|
variable
|
category
|
PFS to EGFR-TKI
|
p-value
|
OS
|
95% CI
|
p-value
|
|---|
|
HR
|
95% CI
|
HR
|
|---|
|
Smoking history
|
ever- smokers vs never smoker
|
1.89
|
1.27–2.81
|
0.002
|
1.52
|
0.87–2.64
|
0.13
|
|
Smoking dosage
|
never smoker
|
1.00
| | |
1.00
| | |
|
≤10 PY
|
0.81
|
0.43–1.50
|
0.49
|
0.83
|
0.32–2.14
|
0.68
|
|
11~ 30 PY
|
4.00
|
1.95–8.23
|
< 0.001
|
1.52
|
0.79–2.96
|
0.21
|
|
> 30 PY
|
16.2
|
6.37–61.6
|
< 0.001
|
3.98
|
1.84–8.28
|
< 0.001
|
- Adjusted by Age, PS, Sex, clinical stage and time of targeted therapy
- Abbreviations: PFS progression-free survival, OS overall survival, Ref. reference, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PS performance status, HR hazard ratio, 95% CI 95% confidence interval, PY pack-years
